{"id":13369,"date":"2023-08-26T15:21:58","date_gmt":"2023-08-26T19:21:58","guid":{"rendered":"http:\/\/sites.bu.edu\/urbanarch\/?page_id=13369"},"modified":"2023-12-04T15:57:36","modified_gmt":"2023-12-04T20:57:36","slug":"newsletter-vol10iss3","status":"publish","type":"page","link":"https:\/\/sites.bu.edu\/urbanarch\/newsletter-vol10iss3\/","title":{"rendered":"Newsletter"},"content":{"rendered":"

Volume 10, Issue 3<\/span><\/h3>\n

July – September 2023<\/span><\/h3>\n
\n

Check out the current issue of URBAN ARCH News<\/em>, the quarterly newsletter bringing you news on the latest URBAN ARCH and related research.<\/strong><\/span><\/h3>\n
\n

The GRAIL Study<\/a><\/h3>\n

\"\"<\/a><\/p>\n

In this edition of the URBAN ARCH Newsletter, we highlight the recently funded Gabapentin to Reduce Alcohol and Improve Viral Load Suppression (GRAIL) study.<\/b><\/span><\/p>\n

\n
\n

Updates from 2nd Generation URBAN ARCH HIV\/Alcohol P01s<\/strong><\/a><\/h3>\n

\"\"<\/a>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0\"\"<\/a><\/p>\n<\/div>\n

\n
\n

International URBAN ARCH Center Updates<\/strong><\/a><\/h3>\n<\/div>\n

Click on the buttons below to see what the International URBAN ARCH Center Cores and Projects have been working on.<\/span><\/p>\n\n\n\n
<\/span><\/a>\"\"<\/a><\/td>\n<\/span><\/a>\"\"<\/a><\/td>\n\"\"<\/a><\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

Spotlight on… Allen Kekibiina<\/a><\/h3>\n

\"\"In this issue, we interview GRAIL field coordinator Allen Kekibiina about her background in the field of HIV and alcohol research, and her current work on the GRAIL study.\u00a0<\/span><\/p>\n

 <\/p>\n

\n

Article Spotlight<\/strong><\/span><\/h3>\n

Alcohol Use Did Not Increase Risk for Serious Isoniazid-related Toxicity Among People With HIV and TB<\/strong><\/p>\n

Among people with HIV (PWH), isoniazid preventative therapy can help prevent tuberculosis (TB) disease. However, isoniazid therapy is not recommended for people with heavy alcohol use, due to concerns about hepatotoxicity. URBAN ARCH researchers in Uganda investigated the incidence of severe isoniazid-related toxicity among a cohort of PWH, some of whom had consumed alcohol within the last 3 months (n=200), and some of whom had no alcohol consumption in the last year (n=101). All participants were receiving antiretroviral therapy, had TB infection, and had alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2\u00d7 or less the upper limit of normal (ULN). Isoniazid-related toxicity was classified thus: Grade 3+ (ALT or AST at least 5\u00d7 the ULN or severe symptoms), or Grade 2 (ALT or AST 2-5\u00d7 the ULN or moderate symptoms).<\/p>\n